SRPT Investors Have Opportunity to Join Sarepta Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES, July 21, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Sarepta admitted on March 18, 2025, that a young patient with Duchenne muscular dystrophy had died "following treatment with ELEVIDYS", the Company's Duchenne muscular dystrophy drug, "having suffered acute liver failure." Based on this news, shares of Sarepta fell by more than 27.4% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm 
Brian Schall, Esq.
310-301-3335
info@schallfirm.com
www.schallfirm.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/srpt-investors-have-opportunity-to-join-sarepta-therapeutics-inc-fraud-investigation-with-the-schall-law-firm-302509326.html

SOURCE The Schall Law Firm